Literature DB >> 36238993

Microarray data reveal potential genes that regulate triple-negative breast cancer.

Chi Pan1, Aihua Cong2, Qingtao Ni2.   

Abstract

OBJECTIVE: Triple-negative breast cancer (TNBC) is characterized by a lack of targeted therapies and poor patient prognosis, and its underlying pathological mechanisms remain unclear. This study aimed to identify potential key genes and related pathways that are required for TNBC development.
METHODS: We screened the Gene Expression Omnibus database for transcriptome data and identified differently expressed genes in TNBC. Then, we performed Gene Ontology analysis to determine the genes and pathways involved in TNBC development. We correlated significantly expressed genes and miRNAs using miRDB, TargetScan, miRWalk, and DIANA, and then validated the expression of CDK1 and miR-143-3p in TNBC patients.
RESULTS: Eighteen genes were significantly upregulated in TNBC patients, and these were found to be enriched in cell metabolic process, cell division, mitochondrion, and respiratory chain. MiR-143-3p was found to be an upstream regulator of CDK1. Validation experiments revealed that CDK1 was upregulated while miR-143-3p was downregulated in clinical TNBC specimens.
CONCLUSIONS: Collectively, our results revealed 18 upregulated genes in TNBC. Notably, CDK1 and its related microRNA miR-143-3p could be potential therapeutic targets for TNBC.

Entities:  

Keywords:  Bioinformatics; CDK1; cell cycle; key genes; miR-143-3p; triple-negative breast cancer

Mesh:

Substances:

Year:  2022        PMID: 36238993      PMCID: PMC9575453          DOI: 10.1177/03000605221130188

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.573


  30 in total

1.  PEG-GO@XN nanocomposite suppresses breast cancer metastasis via inhibition of mitochondrial oxidative phosphorylation and blockade of epithelial-to-mesenchymal transition.

Authors:  Jialing Zhang; Liang Yan; Peng Wei; Ruyi Zhou; Chaoju Hua; Min Xiao; Yaping Tu; Zhanjun Gu; Taotao Wei
Journal:  Eur J Pharmacol       Date:  2021-01-14       Impact factor: 4.432

2.  Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.

Authors:  Yi Li; Xuexia Zhang; Jiliang Qiu; Ting Pang; Lin Huang; Qingan Zeng
Journal:  J BUON       Date:  2019 Nov-Dec       Impact factor: 2.533

3.  MiR-143-3p inhibits the proliferation, cell migration and invasion of human breast cancer cells by modulating the expression of MAPK7.

Authors:  Chongsheng Xia; Ya Yang; Fanhua Kong; Qingli Kong; Changping Shan
Journal:  Biochimie       Date:  2018-01-31       Impact factor: 4.079

4.  National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer.

Authors:  Christopher P Childers; Kimberly K Childers; Melinda Maggard-Gibbons; James Macinko
Journal:  J Clin Oncol       Date:  2017-08-18       Impact factor: 44.544

Review 5.  Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment.

Authors:  Guowei Gu; Derek Dustin; Suzanne Aw Fuqua
Journal:  Curr Opin Pharmacol       Date:  2016-11-22       Impact factor: 5.547

6.  MiR-143-3p Increases the Radiosensitivity of Breast Cancer Cells Through FGF1.

Authors:  Dewen Wang; Chunying Wang; Lei Sun; Xiang Lu; Jiangwei Shi; Jing Chen; Xuesong Zhang
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  2022-02-04       Impact factor: 1.206

7.  Nucleolar and Spindle Associated Protein 1 (NUSAP1) Inhibits Cell Proliferation and Enhances Susceptibility to Epirubicin In Invasive Breast Cancer Cells by Regulating Cyclin D Kinase (CDK1) and DLGAP5 Expression.

Authors:  Xi Zhang; Yuliang Pan; Huiqun Fu; Juan Zhang
Journal:  Med Sci Monit       Date:  2018-11-26

8.  MYBL2 Is Targeted by miR-143-3p and Regulates Breast Cancer Cell Proliferation and Apoptosis.

Authors:  Jianli Chen; Xiaowen Chen
Journal:  Oncol Res       Date:  2017-12-21       Impact factor: 5.574

Review 9.  Cancer Stem Cell-Associated Pathways in the Metabolic Reprogramming of Breast Cancer.

Authors:  Sara El-Sahli; Lisheng Wang
Journal:  Int J Mol Sci       Date:  2020-11-30       Impact factor: 5.923

10.  A Pan-Cancer Analysis of SMARCA4 Alterations in Human Cancers.

Authors:  Ling Peng; Jisheng Li; Jie Wu; Bin Xu; Zhiqiang Wang; Georgios Giamas; Justin Stebbing; Zhentao Yu
Journal:  Front Immunol       Date:  2021-10-04       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.